Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| NGG | -0.29% | 65.38 | $ | |
| JRI | 0.5% | 12.935 | $ | |
| AZN | -1.58% | 72.645 | $ | |
| SCS | 0.75% | 11.184 | $ | |
| BCC | -0.22% | 98.085 | $ | |
| CMSC | -0.28% | 22.4 | $ | |
| RBGPF | 1.47% | 68 | $ | |
| GSK | -1.35% | 38.225 | $ | |
| BTI | 1.5% | 41.125 | $ | |
| RIO | -2.62% | 59.47 | $ | |
| RYCEF | -2.16% | 9.7 | $ | |
| BCE | 0.41% | 23.065 | $ | |
| BP | -0.16% | 33.805 | $ | |
| VOD | -0.59% | 9.395 | $ | |
| RELX | -0.15% | 50.085 | $ | |
| CMSD | -0.13% | 22.681 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
N.Handrahan--NG
